Although the Phase II acelERA BC trial of giredestrant missed statistical significance for its primary endpoint of investigator‐assessed PFS, a favorable benefit trend was observed in patients with ESR1‐mutant tumors, the finding that provides a strong rationale for the ongoing Phase III programme [111]. This evidence concerns the gene ESR1 and breast cancer.